Julia Caroline相关文献与解析，生知库 | 链接生命科学的每一步

Begnini, Karine Rech; Marcolin, Julia Caroline; Pereira, Luiza Cherobini; de Souza, Letícia Cunha Pereira; Kraemer-Mattos, Frederico; Tórgo, Daphne; Machemer, Carolina; da Silva Goulart, Georgia; Silva, Andrew Oliveira; Dos Santos, Jephesson Alex Floriano; Lenz, Guido

胶质瘤

MAPK/ERK

细胞生物学

发表日期：2026

文献求助收藏

Validation of biomarkers and clinical scores for the detection of uterine leiomyosarcoma: a case-control study with an update of pLMS

子宫平滑肌肉瘤检测中生物标志物和临床评分的验证：一项病例对照研究及pLMS更新

期刊:BMC Cancer

影响因子:3.4

doi:10.1186/s12885-024-13396-y

Vollmer, Marcus; Köhler, Günter; Radosa, Julia Caroline; Zygmunt, Marek; Zimmermann, Julia; Köller, Martina; Seitz, Christine; Bralo, Helena; Radosa, Marc Philipp; Kaya, Askin Cangül; Krichbaum, Johann; Solomayer, Erich-Franz; Kaderali, Lars; Alwafai, Zaher

多发性硬化症

发表日期：2025

文献求助收藏

Women with first recurrence of endometrial cancer: who are they? An analysis of real-world data of the JAGO/NOGGO

首次复发子宫内膜癌的女性：她们是谁？JAGO/NOGGO真实世界数据分析

期刊:BMC Cancer

影响因子:3.4

doi:10.1186/s12885-025-15168-8

Proppe, Louisa; Zimmermann, Julia Sarah Maria; Hachenberg, Jens; Pan, Teresa; Tsibulak, Irina; Radosa, Julia Caroline; Botscharnikow, Christine; Flethe, Chiara; Sehouli, Jalid; Pietzner, Klaus

Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs

每月参与临床试验的患者入组人数（入组人数），这些试验最终将获得FDA批准用于新的癌症药物

期刊:Targeted Oncology

影响因子:4

doi:10.1007/s11523-024-01081-w

Michaeli, Daniel Tobias; Michaeli, Thomas; Albers, Sebastian; Michaeli, Julia Caroline

Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy

美国食品药品监督管理局 (FDA) 对药物研发的特殊认定：孤儿药资格、快速通道资格、加速审批资格、优先审评资格和突破性疗法资格。

期刊:European Journal of Health Economics

影响因子:3

doi:10.1007/s10198-023-01639-x

Michaeli, Daniel Tobias; Michaeli, Thomas; Albers, Sebastian; Boch, Tobias; Michaeli, Julia Caroline

发表日期：2024

文献求助收藏

Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price

乳腺癌药物：FDA批准、研发时间、疗效、临床获益、创新性、临床试验、终点指标、生活质量、价值和价格

期刊:Breast Cancer

影响因子:2.9

doi:10.1007/s12282-024-01634-x

Michaeli, Julia Caroline; Michaeli, Thomas; Trapani, Dario; Albers, Sebastian; Dannehl, Dominik; Würstlein, Rachel; Michaeli, Daniel Tobias

Correlation of preoperative sonographic staging and postoperative histopathologic staging in patients with invasive breast cancer

浸润性乳腺癌患者术前超声分期与术后组织病理学分期的相关性

期刊:Archives of Gynecology and Obstetrics

影响因子:2.5

doi:10.1007/s00404-024-07699-5

Mueller, Carolin; Zimmermann, Julia Sarah Maria; Radosa, Marc Philipp; Hahn, Anna Katharina; Kaya, Askin Canguel; Huwer, Sarah; Stotz, Lisa; Wagenpfeil, Gudrun; Radosa, Christoph Georg; Solomayer, Erich-Franz; Radosa, Julia Caroline

Advances in cancer therapy: clinical benefit of new cancer drugs

癌症治疗进展：新型抗癌药物的临床获益

期刊:Aging-Us

影响因子:3.9

doi:10.18632/aging.204839

Michaeli, Daniel Tobias; Michaeli, Julia Caroline; Michaeli, Thomas

Preoperative Sonographic Prediction of Limited Axillary Disease in Patients with Primary Breast Cancer Meeting the Z0011 Criteria: an Alternative to Sentinel Node Biopsy?

术前超声预测符合 Z0011 标准的原发性乳腺癌患者腋窝淋巴结局限性病变：前哨淋巴结活检的替代方案？

期刊:Annals of Surgical Oncology

影响因子:3.5

doi:10.1245/s10434-022-11829-1

Radosa, Julia Caroline; Solomayer, Erich-Franz; Deeken, Martin; Minko, Peter; Zimmermann, Julia Sarah Maria; Kaya, Askin Canguel; Radosa, Marc Philipp; Stotz, Lisa; Huwer, Sarah; Müller, Carolin; Karsten, Maria Margarete; Wagenpfeil, Gudrun; Radosa, Christoph Georg

ASO Author Reflections: An Alternative to Sentinel-Node Biopsy? Preoperative Sonographic Prediction of Limited Axillary Disease in Breast Cancer Patients Meeting the Z0011 Criteria

ASO作者反思：前哨淋巴结活检的替代方案？术前超声预测符合Z0011标准的乳腺癌患者腋窝淋巴结局限性转移

期刊:Annals of Surgical Oncology

影响因子:3.5

doi:10.1245/s10434-022-11845-1

Temozolomide increases the generation of cell heterogeneity in ERK activity in glioma cells

替莫唑胺可增加胶质瘤细胞中ERK活性的细胞异质性。

Validation of biomarkers and clinical scores for the detection of uterine leiomyosarcoma: a case-control study with an update of pLMS

子宫平滑肌肉瘤检测中生物标志物和临床评分的验证：一项病例对照研究及pLMS更新

Women with first recurrence of endometrial cancer: who are they? An analysis of real-world data of the JAGO/NOGGO

首次复发子宫内膜癌的女性：她们是谁？JAGO/NOGGO真实世界数据分析

Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs

每月参与临床试验的患者入组人数（入组人数），这些试验最终将获得FDA批准用于新的癌症药物

Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy

美国食品药品监督管理局 (FDA) 对药物研发的特殊认定：孤儿药资格、快速通道资格、加速审批资格、优先审评资格和突破性疗法资格。

Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price

乳腺癌药物：FDA批准、研发时间、疗效、临床获益、创新性、临床试验、终点指标、生活质量、价值和价格

Correlation of preoperative sonographic staging and postoperative histopathologic staging in patients with invasive breast cancer

浸润性乳腺癌患者术前超声分期与术后组织病理学分期的相关性

Advances in cancer therapy: clinical benefit of new cancer drugs

癌症治疗进展：新型抗癌药物的临床获益

Preoperative Sonographic Prediction of Limited Axillary Disease in Patients with Primary Breast Cancer Meeting the Z0011 Criteria: an Alternative to Sentinel Node Biopsy?

术前超声预测符合 Z0011 标准的原发性乳腺癌患者腋窝淋巴结局限性病变：前哨淋巴结活检的替代方案？

ASO Author Reflections: An Alternative to Sentinel-Node Biopsy? Preoperative Sonographic Prediction of Limited Axillary Disease in Breast Cancer Patients Meeting the Z0011 Criteria

ASO作者反思：前哨淋巴结活检的替代方案？术前超声预测符合Z0011标准的乳腺癌患者腋窝淋巴结局限性转移